Menu
Start Screening

Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

Depression Clinical trial The British Journal of Psychiatry

1 paper

Depression

Based on 77 papers

Research on treating depression is moving fast. Right now the clearest clinical evidence is for ketamine and its FDA‑approved form esketamine, which can lift symptoms quickly but often only for days or weeks. Classic psychedelics like psilocybin, and related compounds such as DMT and 5‑MeO‑DMT, show strong early promise when given with psychotherapy. However, most psychedelic studies are still small or early‑stage and need larger, well‑controlled trials. Other approaches are being tested too. MDMA‑assisted therapy has strong, growing evidence for post‑traumatic stress disorder and can also reduce some depressive symptoms, but some pooled reports have been retracted and long‑term safety and broad applicability need more study. Brain‑stimulation methods (deep brain stimulation, vagus nerve stimulation, transcranial magnetic stimulation) and combined treatments (for example ketamine plus TMS) show mixed or preliminary results. Across all these lines of research, the therapy, setting, and careful medical oversight matter. Studies also often lack diversity and long‑term follow‑up, so we cannot assume the results apply to everyone yet.

Key findings

  • Ketamine can reduce depressive symptoms within hours and often peaks around 24 hours, but the effect commonly fades after about 10–12 days without repeated treatment. 15070 12156
  • An intranasal form of esketamine has been approved by regulators for treatment‑resistant depression and for depression with acute suicidal thoughts, and trials show it can speed symptom improvement when added to a new oral antidepressant. 15070 12156
  • Clinical trials of psilocybin given with psychotherapy have repeatedly shown benefits for major depression and for anxiety and depression in people facing life‑threatening illness, but authors say larger, well‑controlled trials are still needed before it becomes a standard treatment. 15132 15056 15060
  • Some late‑stage psilocybin trials received special regulatory attention (so‑called 'Breakthrough Therapy' status), which shows strong interest but not proof of broad effectiveness or safety yet. 15049
  • MDMA‑assisted psychotherapy has produced large, positive results in trials for PTSD and has reduced related depressive symptoms in some studies; however, a pooled analysis paper listed here was later retracted, and more transparent, confirmatory data are important. 15063 15086 13467
  • The success of psychedelic or entactogen treatments is strongly linked to non‑drug factors: people’s mindset, the therapy and preparation before and after the drug session, and the physical and social setting (often called 'set and setting'). 15086 15065 15096
  • Lab and animal studies show psychedelics and ketamine can boost brain plasticity (the brain’s ability to form new connections) and reduce some markers of inflammation; but a human meta‑analysis found no consistent change in blood BDNF levels after these drugs, highlighting limits of current biological measures. 15050 15091 15129
  • Brain‑stimulation treatments show mixed evidence: small deep brain stimulation studies reported big improvements in small groups, a large one‑year vagus nerve stimulation trial had mixed main results, and combining TMS with ketamine is an early idea that needs more testing. 10166 10163 10162
  • Safety and long‑term effects are not fully known. Reports include short‑term physical or psychological side effects in trials, rare but serious risks with some drugs (for example ibogaine's cardiac risks), and persistent perception problems after hallucinogens (HPPD) in case reports. 15135 15085 15048
  • Many psychedelic studies have included mostly White participants. Researchers point out a need for much better inclusion of people of color and diverse cultural perspectives before we can know how well these treatments work for everyone. 15095 15094

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial

Colleen Loo, Nick Glozier, Dávid Barton, Bernhard T. Baune, Natalie Mills, Paul B. Fitzgerald, et al.
The British Journal of Psychiatry Summary & key facts 2023 60 citations

Researchers tested repeated subcutaneous (under-the-skin) injections of racemic ketamine in people whose depression had not improved after at least two antidepressant trials. People got injections twice a week for 4 weeks and neither participants nor the raters knew which drug they were getting. When the study allowed higher, response-guided ketamine…

Mental Health Research Topics Treatment of Major Depression Tryptophan and brain disorders Ketamine
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.